SynthesisInternational urology and nephrology2025
Liquid-based kidney injury molecule-1 as a diagnostic and prognostic indicator in renal cell carcinoma: A systematic review and meta-analysis.
Synthesis in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Kidney Injury Molecule-1 (KIM-1) in Renal Cell Carcinoma: Biological Foundations and Emerging Clinical Applications.Current oncology (Toronto, Ont.) · 2026Review
- KIM-1 as a Biomarker in Genitourinary Neoplasms.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeNoninvasive biomarkers for renal cell carcinoma (RCC) are vital but scarce. Kidney injury molecule-1 (KIM-1) is a transmembranous glycoprotein that is sensitive and specific to kidney injury. KIM-1 is overexpressed in RCC, and its ectodomain can be detected in blood and urine. Here, we explored whether KIM-1 is a diagnostic or prognostic indicator in RCC.
methodsA comprehensive online literature search was performed in PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrails, and Database of major urological or oncological congress. We screened the literature and extracted the data according to the selection criteria. The quality of eligible studies was measured via the Quality Assessment of Diagnostic Accuracy Studies-2 tool and the Newcastle-Ottawa scale. The certainty of the evidence (CoE) was assessed by the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) score. The sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), area under the curve of the summary receiver operating characteristic curve (AUROC), and survival outcomes were subsequently estimated in Stata and MetaDisc. Subgroup analysis, meta-regression, and sensitivity analysis were performed to reveal the source of heterogeneity.
resultsA total of eight studies were included for further analysis. The pooled sensitivity of KIM-1 for RCC diagnosis was 0.78 (95% CI: 0.69-0.85, I
conclusionLiquid-based KIM-1 is a promising noninvasive biomarker for early RCC detection, surveillance, and prognosis prediction. More validations in large cohorts are needed to confirm these findings.
Indexed as
Identifiers
40117075What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.